Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -35

Zoetisโ€™ Valuation Has Fallen Sharply, but Has the Market Overreacted?

Earnings report Guidance lowered AI-generated analysis

๐Ÿ“‰ Zoetis shares have dropped over 45% in the past year as weaker U.S. companion-animal demand pressured results and revised earnings forecasts.

๐Ÿ’ฐ The stock now trades at a forward P/E of approximately 12x, down from 21.69x as of September 30, 2025, reflecting a much cheaper valuation.

๐Ÿ“Š Second-quarter 2026 revenue was $2.5 billion, essentially flat year-over-year, with organic operational revenue declining by 1%.

๐Ÿ“‰ Zoetis revised its full-year 2026 guidance to expect organic operational revenue growth of (3)% to (1)% and adjusted diluted EPS of $6.15 to $6.25.

๐Ÿพ U.S. companion-animal product sales fell 11% in the second quarter due to lower clinic visits, price sensitivity, and generic competition affecting products like Cerenia.

๐Ÿ„ Livestock products provided a bright spot with U.S. sales increasing 23%, supported by cattle and poultry demand.

๐ŸŒ International revenue rose 8% on a reported basis and 6% organically, while international companion-animal product sales increased 5% organically.

๐Ÿ’Š Zoetis has more than 12 potential blockbuster candidates in its pipeline targeting chronic kidney disease, oncology, cardiology, anxiety, and obesity.

๐Ÿ”ฌ The company completed the acquisition of VitalRADS to expand its veterinary teleradiology platform into diagnostics.

โœ… Dectomax-CA1 received FDA conditional approval for preventing and treating screwworm myiasis in beef cattle.

Bullish Signals
  • Zoetis trades at a significantly lower forward P/E of approximately 12x compared to 21.69x a year ago, offering a cheaper valuation despite the slowdown.
  • U.S. sales of livestock products increased 23% in the second quarter, supported by strong demand for cattle and poultry products.
  • International revenue rose 8% on a reported basis and 6% organically, demonstrating resilience outside the struggling U.S. companion-animal market.
  • The company possesses a robust pipeline with more than 12 potential blockbuster candidates targeting high-value areas like oncology, cardiology, and chronic kidney disease.
  • Zoetis successfully expanded its diagnostics business by acquiring VitalRADS to enhance veterinary imaging interpretation capabilities.
  • Dectomax-CA1 received FDA conditional approval for a new indication in beef cattle, highlighting the strategic relevance of its existing portfolio.
Risk Factors
  • Zoetis has materially reduced its 2026 earnings expectations, signaling a more conservative view of future growth due to current market conditions.
  • U.S. revenue declined 7% in the second quarter, with companion-animal product sales falling 11% due to lower clinic visits and price sensitivity.
  • Organic operational revenue declined by 1% and adjusted net income fell by 2%, indicating a meaningful slowdown in core business performance.
  • Generic competition is weighing on key products like Cerenia and Convenia, eroding market share and pricing power in the companion-animal segment.
Full Analysis
Zoetis Inc. (NYSE: ZTS) has experienced a sharp decline in valuation, losing over half its value and trading at a forward P/E of approximately 12x compared to 21.69x a year ago. This significant drop is driven by weaker demand in its U.S. companion-animal business, which pressured earnings forecasts and caused the stock price to fall more than 45% over the past 12 months. The company reported second-quarter 2026 revenue of $2.5 billion, essentially flat year-over-year, with organic operational revenue declining by 1%. Adjusted diluted EPS was $1.87, while adjusted net income declined by 2%. Consequently, Zoetis has materially reduced its full-year 2026 guidance, expecting organic operational revenue growth of (3)% to (1)% and adjusted diluted EPS between $6.15 and $6.25. The primary headwind is concentrated in the U.S. companion-animal market, where revenue fell 7% in the second quarter due to lower clinic visits, price sensitivity among pet owners, and heightened competition from generic products like Cerenia and Convenia. However, the company shows resilience in other segments, with U.S. livestock product sales increasing 23% and international revenue rising 8% on a reported basis. Zoetis maintains long-term growth potential through its pipeline of over 12 potential blockbuster candidates targeting areas such as chronic kidney disease, oncology, and cardiology. Additionally, the company is expanding its diagnostics business following the acquisition of VitalRADS and has received regulatory approvals for new products like Dectomax-CA1 to address specific animal health threats.